Trial Profile
Phase 2 Study of ADI PEG 20 in Non-Hodgkins Lymphoma Subjects Who Have Failed Prior Systemic Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegargiminase (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Polaris Pharmaceuticals
- 13 Apr 2016 Status changed from active, no longer recruiting to completed.
- 02 Mar 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
- 02 Mar 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov.